ViaDerma, Inc. VDRM

Company Overview

ViaDerma, Inc. (OTC Pink: VDRM) is a U.S.-based specialty pharmaceutical and biotechnology company focused on transdermal drug delivery technologies. The company’s primary activity has centered on the development and commercialization of topical and transdermal antibiotic therapies, particularly products utilizing tetracycline-based formulations designed to improve absorption through the skin. ViaDerma operates within the broader healthcare, pharmaceutical, and dermatology markets, with an emphasis on wound care, skin infections, and anti-inflammatory applications.

The company’s principal product platform has been associated with Vitastem, a topical tetracycline formulation promoted for wound management and dermatological use. Public disclosures indicate that ViaDerma has historically targeted healthcare providers, clinics, and potential licensing or distribution partners rather than large-scale direct consumer pharmaceutical sales. ViaDerma evolved from an early-stage development company into a microcap healthcare issuer focused on commercialization partnerships and intellectual property development. Publicly available information regarding long-term revenue scale, sustained profitability, and commercial penetration remains limited, and some operational details are inconclusive based on available public sources.